Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence.

Sariya UdayachalermMaranda G RenouardThunyarat Anothaisintawee Ammarin Thakkinstian Sajesh K Veettil Nathorn Chaiyakunapruk

Published in: Journal of medical economics (2021)

RZV may be cost-effective for vaccination in ages of 60-79 years for both SP and TPP perspectives, while ZVL might be cost-effective in some age groups, but results are not robust.

Keyphrases